Hims & Hers Shares Plunge. Is This a Buying Opportunity or Should Investors Run for the Hills?

Hims & Hers Health reported Q2 revenue of $544.8 million, a 73% year-over-year increase, which missed analyst expectations and contributed to share volatility. Despite the revenue miss, the company exceeded adjusted EPS at $0.17 and more than doubled adjusted EBITDA to $82.2 million, driven by a 31% surge in subscribers and increased personalized treatment plans. While GLP-1 revenue declined following a partnership change, HIMS maintained its robust 2025 guidance and outlined ambitious long-term targets, emphasizing continued growth through international expansion and new health categories, positioning it as a high-growth, albeit volatile, play with a seemingly reasonable valuation given its trajectory.

Analysis

Hims & Hers Health (HIMS) reported a mixed second quarter, characterized by robust operational growth offset by a revenue figure that narrowly missed analyst expectations, fueling significant stock volatility. The company delivered a 73% year-over-year revenue increase to $544.8 million, driven by a 31% expansion of its subscriber base to 2.44 million and a 30% rise in monthly online revenue per subscriber to $74. Despite the top-line miss, HIMS demonstrated improving profitability, with adjusted EBITDA more than doubling to $82.2 million and adjusted EPS of $0.17 surpassing the $0.15 consensus. A key strategic positive is the growing adoption of personalized subscriptions, which now constitute over 60% of the subscriber base and show strong traction with new patients. While the termination of its partnership with Novo Nordisk resulted in a sequential quarterly decline in GLP-1 revenue to $190 million, the company maintained its full-year guidance and is pivoting to oral weight loss solutions. Furthermore, marketing expenses as a percentage of revenue declined from 46% to 40% year-over-year, indicating increasing operational leverage. The company's decision to maintain its strong full-year 2025 guidance, projecting revenue of $2.3 billion to $2.4 billion, underscores its confidence, supported by plans for international expansion and new service lines like hormonal health.

Key Decisions for Investors

• Investors should weigh the company's powerful growth trajectory and improving profitability against the significant stock volatility, which is heightened by its sensitivity to meeting high market expectations.
• Monitor the company's execution on its pivot to oral weight loss products and the continued growth in personalized subscriptions, as these are critical to validating the long-term margin and revenue story.
• For those with a high-risk tolerance, the stock's forward PEG ratio below 0.6 suggests a potentially attractive valuation for a high-growth name, but this must be balanced against the execution risk tied to its ambitious international expansion and new product launches.
• Consider the revenue miss a key data point on execution risk; any position should be sized to account for potential volatility around future earnings reports and news related to the competitive telehealth and weight loss markets.